Advertisment
Bayer to present comprehensive findings on Finerenone from FINEARTS-HF trial at CVCT 2024
Bayer announced that new analyses from the Phase III FINEARTS-HF trial evaluating finerenone (Kerendia) in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥ 40% will be presented at the Cardiovascular Clinical Trials (CVCT) Forum, taking place in Washington, D.C. from December 9-11, 2024.
Data being presented at CVCT 2024 include the following. All posters will be presented at the poster session on Tuesday, December 10th from 7:30 – 9:00 pm EST:
Blood Pressure Effects of Finerenone in HFmrEF/HFpEF
Blood pressure optimization is a guideline-recommended priority of heart failure (HF) care. A new prespecified analysis of the FINEARTS-HF trial in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) evaluated the effect of finerenone, a non-steroidal MRA, on systolic blood pressure overall and in individuals with apparent treatment-resistant hypertension, as well as the relationship between the effects of finerenone on blood pressure and clinical outcomes.
- Blood pressure effects of finerenone in heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial
Effect of Finerenone on Outpatient Worsening Heart Failure Events
Outpatient worsening HF events are common and associated with poor subsequent prognosis. This analysis investigated the effect of finerenone on outpatient worsening HF events in patients with HF and mildly reduced or preserved ejection fraction.
- Effect of Finerenone on Outpatient Worsening Heart Failure Events in Patients with Mildly Reduced or Preserved Ejection Fraction
Effect of Finerenone and Number of Hospitalizations
Recency of a heart failure hospitalization is associated with readmission and death in patients with heart failure. Number of prior hospitalizations due to heart failure may be an additional predictor of outcomes.
- Number of hospitalizations and effect of Finerenone in FINEARTS-HF
Impact of Body Mass Index on Finerenone’s Efficacy
Obesity is associated with increased aldosterone secretion, making mineralocorticoid receptor antagonists (MRAs) potentially more effective in obese heart failure patients. This study compared the effects of finerenone versus placebo across different BMI categories in the FINEARTS-HF trial.
- Effect of Finerenone in Patients With HFmrEF/HFpEF According to Body Mass Index: A Prespecified Analysis of the FINEARTS-HF Trial
Initial eGFR Decline with Finerenone
An initial decline in estimated glomerular filtration rate (eGFR) often leads to reluctance to continue the life-saving therapy in patients with HF. However, this early dip in eGFR has been shown to predict a favorable response to several HF therapies. This study analyzed early change in eGFR and outcomes in patients treated with finerenone versus placebo.
- Initial decline (dip) in estimated glomerular filtration rate with initiation of finerenone in patients with mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF Trial
Finerenone and Frailty in Heart Failure
Patients with frailty are often perceived to have a less favorable benefit-risk profile, and therefore may be less likely to receive new treatments. This study investigated the efficacy and tolerability of finerenone according to frailty status in patients with HF with mildly reduced or preserved ejection fraction in the FINEARTS-HF trial.
- Finerenone and frailty in heart failure with mildly reduced or preserved ejection fraction: An analysis from FINEARTS-HF
Participant-level Pooled Analysis of Finerenone in Heart Failure Across Three Phase III trials (FINE-HEART)
In this prespecified participant-level pooled analysis, efficacy and safety of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction was evaluated across three Phase III studies, using Cox proportional hazards models stratified by trial.
- Efficacy and Safety of Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Participant-Level Pooled Analysis of Three Randomized Clinical Trials
